Discovering Tomorrow's Medicines Today
Novimmune
Novimmune is a, research driven, biopharmaceutical company based in Geneva focused on developing new, anti-body based medicines for rare, inflammatory and autoimmune diseases.
Hemophagiocytic Lymphohistiocytosis (HLH) is a rare, immune system dysfunction which affects mainly children and is associated with a high mortality rate (40-50%). The only cure is a Bone Marrow Transplant, but the HLH flare needs to be shut down first before a BMT can be performed. Novimmune is developing the first medicine designed to treat HLH. NI-0501 is in phase 2 clinical trials and it is anticipated that it could be approved in Q4 2017. The phase 3 trial will start in Q2 2016 in 23 sites in the US and EU.
